ArticleBMC pharmacology & toxicology2024

A real-world disproportionality analysis of the US Food and Drug Administration (FDA) adverse event reporting system (FAERS) events for Durvalumab.

Ting Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.